

# ACTIV Public-Private Partnership

## ACTIV Partnership Leadership Group

## ACTIV Executive Committee

### Co-Chairs

- Larry Tabak, NIH
- William Pao, Roche

### Members

- Gary Disbrow, BARDA
- Mikael Dolsten, Pfizer
- Anthony Fauci, NIH
- Gary Gibbons, NIH
- Peter Marks, FDA
- Gary Dubin, Takeda
- Janet Woodcock, FDA

### Preclinical Working Group

- Animal Models
- In Vitro Assays
- Mutation Tracking

### Therapeutics Clinical Working Group

- Agent Prioritization
- Master Protocol

### Clinical Trial Capacity Working Group

- Survey Development
- Clinical Trial Network Inventory
- Design Innovations

### Vaccines Working Group

- Vaccines Clinical Trials
- Protective Immune Responses
- Vaccine-Associated Immune Enhancement
- Impact of Vaccines on Transmission
- Correlates of Protection

### TRACE Working Group

- Variant emergence monitoring
- Resistance testing
- Data sharing

ACTIV Database & Inventory Effort